Perimenopause Treatment in the UK vs USA: Key Differences Explained
UK and USA approaches to perimenopause treatment differ in significant ways. Compare HRT access, specialist care, and guidelines in both countries.
Why Treatment Varies So Much Between Countries
Perimenopause affects women everywhere, but how it is recognised, treated, and supported varies considerably depending on where you live. The UK and USA have both undergone significant shifts in their approach to hormone therapy over the past decade, moving away from the fear-based prescribing that followed the 2002 Women's Health Initiative study toward a more nuanced understanding of benefits and risks. Despite this shared direction of travel, the two systems differ in meaningful ways in terms of access, cost, available treatments, and clinical guidelines. Understanding those differences helps women in both countries advocate more effectively for themselves.
HRT Access and Prescribing Culture in the UK
In the UK, HRT is available on NHS prescription, and since 2023 a pre-payment certificate allows women to access all HRT prescriptions for a fixed annual fee of around 32 pounds, making it significantly more affordable than in many other countries. The NICE guideline NG23, updated in 2019 and with further updates ongoing, supports offering HRT to most perimenopausal women with troublesome symptoms and advises that the risks have been overstated in the past. Body-identical HRT, including oestradiol gels, patches, and sprays with micronised progesterone (Utrogestan), is now widely prescribed and considered the preferred approach by many UK menopause specialists. The British Menopause Society and Menopause Charity have been influential in improving awareness and access.
HRT Access and Prescribing Culture in the USA
In the USA, HRT access is tied to insurance coverage and prescribing confidence among individual physicians, which varies widely. The Menopause Society (formerly NAMS) and the Endocrine Society support HRT for healthy women under 60 or within 10 years of menopause onset, but many US primary care physicians remain cautious due to the legacy of the WHI findings. Bioidentical compounded hormones have a strong market in the USA, often accessed through functional medicine clinics and concierge practices, but regulatory oversight of compounded preparations is less consistent than for pharmaceutical-grade HRT. The cost of HRT without adequate insurance coverage can be substantial. Telehealth menopause platforms such as Midi Health and Alloy have expanded access significantly in recent years, offering a more affordable route to prescribing for many American women.
Specialist Care: Menopause Clinics and GP Training
In the UK, NHS menopause clinics exist in most regions, though waiting times can be long. The British Menopause Society accredits practitioners at different levels of training, and GP training on menopause has improved following advocacy campaigns. Private menopause clinics have proliferated, with consultations typically ranging from 150 to 300 pounds. In the USA, there is no single equivalent accreditation body, but The Menopause Society offers a practitioner certification (NCMP). Ob-Gyns typically have more menopause training than generalists, but access depends heavily on insurance and geography. Rural and underserved communities in both countries face greater barriers to specialist care. Telehealth has been particularly transformative in the USA, where geography has always been a larger factor in healthcare access.
Non-Hormonal Treatment Options
Both countries have seen growing interest in non-hormonal options for women who cannot or prefer not to take HRT. Fezolinetant (a neurokinin B receptor antagonist, brand name Veoza in the UK and Veozah in the USA) was approved in both countries in 2023 as the first non-hormonal drug specifically licensed for hot flashes. SSRIs, SNRIs, gabapentin, and clonidine are used in both systems for hot flash management, though their evidence base for perimenopause symptoms beyond hot flashes is more limited. Cognitive behavioural therapy for menopause is explicitly recommended in NICE guidelines in the UK and has NHS-funded options in some regions, representing a more structured integration of psychological support than typically seen in US standard care.
Diet, Lifestyle, and Integrative Approaches
Both countries are seeing increased integration of lifestyle medicine into perimenopause care, including nutritional guidance, exercise recommendations, and mindfulness-based approaches. Registered dietitians and health coaches with menopause training are growing in both markets. The USA has a larger market for functional medicine and supplement-based approaches, reflecting both cultural preferences and the higher cost of pharmaceutical care. In the UK, NHS health coaching and weight management services occasionally address perimenopause, though provision is patchy. Both systems have significant room to improve the integration of dietary, psychological, and physical wellbeing support alongside hormonal treatment.
What Women in Both Countries Can Do Right Now
Regardless of where you live, informed self-advocacy is the most powerful tool available. Know the current guidelines in your country, bring a written symptom list to appointments, and ask specifically about body-identical HRT options if that is relevant to your situation. In the UK, the Menopause Charity and Menopause Support websites offer up-to-date GP letter templates and information. In the USA, The Menopause Society's Find a Provider tool and newer telehealth platforms have reduced the geographic barriers to specialist prescribing. Treatment access is improving in both countries, and the conversation has shifted decisively toward taking perimenopausal symptoms seriously rather than dismissing them as a normal part of ageing.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.